Nanomedicine and the complement paradigm.

UNLABELLED The role of complement in idiosyncratic reactions to nanopharmaceutical infusion is receiving increasing attention. We discuss this in relation to nanopharmaceutical development and the possible use of complement inhibitors to prevent related adverse reactions. We further call on initiation of genetic association studies to unravel the genetic basis of nanomedicine infusion-related adverse responses, since most of the polymorphic genes in the genome belong to the immune system. FROM THE CLINICAL EDITOR In this paper, idiosyncratic reactions based on complement activation are discussed in the context of newly available complement inhibitors.

[1]  J Szebeni,et al.  Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. , 2001, International immunopharmacology.

[2]  Dan Peer,et al.  Reshaping the future of nanopharmaceuticals: ad iudicium. , 2011, ACS nano.

[3]  John D Lambris,et al.  Recent developments in low molecular weight complement inhibitors. , 2009, Molecular immunology.

[4]  Y. Barenholz,et al.  Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  S. Moghimi,et al.  Nanotechnology: from fundamental concepts to clinical applications for healthy aging. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[6]  Yechezkel Barenholz,et al.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.

[7]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  J Szebeni,et al.  Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. McCluskey,et al.  Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. , 2012, Annual review of pharmacology and toxicology.

[10]  S Moein Moghimi,et al.  Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. , 2010, ACS nano.

[11]  S M Moghimi,et al.  Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. , 2012, Annual review of pharmacology and toxicology.

[12]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[13]  Davoud Ahmadvand,et al.  Material properties in complement activation. , 2011, Advanced drug delivery reviews.

[14]  J. Szebeni,et al.  Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes. , 2012, Chemistry and physics of lipids.

[15]  Hongjie Dai,et al.  Single-walled carbon nanotube surface control of complement recognition and activation. , 2013, ACS nano.

[16]  Sheng Li,et al.  Allosteric inhibition of complement function by a staphylococcal immune evasion protein , 2010, Proceedings of the National Academy of Sciences.

[17]  A. Daly.  Using genome-wide association studies to identify genes important in serious adverse drug reactions. , 2012, Annual review of pharmacology and toxicology.

[18]  John D. Lambris,et al.  Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine , 2011, The Journal of Immunology.

[19]  S. Moghimi,et al.  Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. , 2012, Advanced drug delivery reviews.

[20]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.